View More Recent Stories
-
3 ways to gain stock market exposure to the fertility theme
-
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
-
Selloff in MedTech stocks 'seems overdone': Citi
-
Abbott (ABT) Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices
-
Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health
-
Midday movers: McDonald's, Tesla, Onsemi rise; Abbott falls
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays
-
UBS Reiterates Buy Rating on Abbott Labs (ABT)
-
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
-
Midday movers: DR Horton, Kinder Morgan rise ; Domino's Pizza, Beyond Meat fall
-
Evercore ISI Reiterates Outperform Rating on Abbott Labs (ABT), PT $120
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT), PT $130
-
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
-
Citi Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Tops Q2 EPS by 3c, Updates Guidance
-
Abbott (ABT) call put ratio 4.9 calls to 1 put into quarter results
-
Abbott (ABT) July 103 straddle into quarter results
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Declares $0.55 Quarterly Dividend; 2.1% Yield
-
Abbott (ABT) Receives FDA Clearance for Two New OTC Continuous Glucose Monitoring Systems
-
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
-
Abbott (ABT) Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
